Investigate the impact of ICAM-2 and Neprilysin biomarkers in prostate cancer patients infected with JC virus in AL-Najaf AL-Ashraf Province

Abstract

A total of 74 clinical samples Formalin-Fixed Paraffin-Embedded (FFPE) were collected from patients diagnosed with prostate cancer (PCa) aged between 41 and 90 years and these samples were obtained from patients treated at notable medical institutions like Al-Sadr Medical City and leading clinical laboratories in Al-Najaf City, Iraq, during the period of January to December 2023. The current study indicated the potential role of the JCV virus in provoking prostatitis, which may lead to the emergence and development of prostate cancer in males compared to males who do not suffer from viral infection. The present study showed the presence of JCV virus DNA, as the percentage of positive samples reached (11, 14.864%) compared to negative samples (63, 85.135%). The current study showed a significant increase in the level of ICAM-2 biomarker in patients with JCV-positive prostate cancer, reaching (818.500±42.748 pg/ml) compared with patients with JCV-negative, reaching (502.925±58.037 pg/ml). Neprilysin (NEP) levels in the current study were significantly high in for JCV-positive patients and those with prostate cancer, reaching (4.275±0.376 pg/ml) compared with JCV-negative patients, reaching (3.131±0.232 pg/ml).